Moexipril indications and usage: Difference between revisions
Amr Marawan (talk | contribs) No edit summary |
Amr Marawan (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
Moexipril HCl and Hydrochlorothiazide Tablets is indicated for treatment of patients with [[hypertension]]. This fixed combination is not indicated for the initial therapy of hypertension. | Moexipril HCl and Hydrochlorothiazide Tablets is indicated for treatment of patients with [[hypertension]]. This fixed combination is not indicated for the initial therapy of hypertension. | ||
In using Moexipril HCl and [[Hydrochlorothiazide Tablets]], consideration should be given to the fact that another ACE inhibitor, [[captopril]], has caused [[agranulocytosis]], particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that Moexipril HCl and [[Hydrochlorothiazide]] Tablets does not have a similar risk. In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of [[angioedema]] in black than in nonblack patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE | In using Moexipril HCl and [[Hydrochlorothiazide Tablets]], consideration should be given to the fact that another ACE inhibitor, [[captopril]], has caused [[agranulocytosis]], particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that Moexipril HCl and [[Hydrochlorothiazide]] Tablets does not have a similar risk. In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of [[angioedema]] in black than in nonblack patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 20:47, 14 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Moexipril
Moexipril and Hydrochlorothiazide tablet
Overview
Moexipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]
Indications and Usage
Moexipril HCl and Hydrochlorothiazide Tablets is indicated for treatment of patients with hypertension. This fixed combination is not indicated for the initial therapy of hypertension.
In using Moexipril HCl and Hydrochlorothiazide Tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that Moexipril HCl and Hydrochlorothiazide Tablets does not have a similar risk. In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients.[1]
References
Adapted from the FDA Package Insert.